Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
Noura J. Choudhury(Memorial Sloan Kettering Cancer Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Pier Selenica(Memorial Sloan Kettering Cancer Center), Glenn Heller(Memorial Sloan Kettering Cancer Center), Mark G. Kris(American Society of Clinical Oncology), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Daniel R. Gomez(The University of Texas MD Anderson Cancer Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Soo‐Ryum Yang(Memorial Sloan Kettering Cancer Center), Jorge S. Reis‐Filho(Memorial Sloan Kettering Cancer Center), Natasha Rekhtman(Albert Einstein College of Medicine), Jessica Flynn(Memorial Sloan Kettering Cancer Center), Antonio Marra(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Christina J. Falcon(Memorial Sloan Kettering Cancer Center), Jane Sze Yin Sui(Memorial Sloan Kettering Cancer Center), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center)
Cited by 95
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k